Abbott's new leadless pacemaker system meets primary endpoints in pivotal trial

Abbott park, ill., nov. 12, 2021 /prnewswire/ -- abbott (nyse: abt) today announced new, late-breaking data from the global leadless ii ide study evaluating abbott's investigational aveir leadless pacemaker in patients with certain abnormal heart rhythms.

ABT Ratings Summary

ABT Quant Ranking